Novavax (NVAX) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.19

Estimate

-$0.35

Surprise

+45.1%

Revenue (period 2026-09-30)

$68.3M

Score today

5.2/10

Revenue source: xbrl.

Novavax (NVAX) reported a narrower loss than forecast — adjusted EPS of -$0.19 against the -$0.35 estimate (a 45.1% beat on a still-unprofitable quarter).

• B. Riley Securities Reiterates Buy on Novavax, Lowers Price Target to $16 — benzinga, 2026-11-06
• Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights — fiscal.ai, 2026-11-05
• Novavax Exec Says Co Is Exploring An Over 50% Reduction To Operating Footprint Via Consolidation Of Buildings And Labora — benzinga, 2026-11-05

TrendMatrix currently rates NVAX Sell at 5.2/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate; this quarter's +45.1% surprise compares with a +66.4% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$10.71

Price target

$12.57

Stop

$9.96

Upside to target

+17.4%

Reward-to-risk

1.2:1

Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.61B

P/E (fwd)

-59.7

52-week range

$6.20–$13.39

Off 52-week high

20.1%

RSI (14)

49

Volume vs avg

0.42×

Score today

5.2/10